Exostemtech approved phase 1 and 2a clinical trials for combination of Kitruda and Exosome inhibitor
- Jul 16, 2021
- 1 min read
Updated: Sep 28, 2022
Exostemtech, a new drug developer, announced on the 16th that it has received approval from the Ministry of Food and Drug Safety for phase 1 and 2a clinical trials in Korea for a combination of cancer exosome inhibitors and immuno-cancer drug Kitruda.
This clinical trial will be conducted at multiple institutions, including St. Mary's Hospital in Seoul, with Kang Jin-hyung, a professor of oncology at Seoul St. Mary's Hospital, who is in charge of clinical research.
Kitruda (component Pembrolizumab) is an immune checkpoint inhibitor, a type of immuno-cancer drug of Merck (MSD) in the United States, that activates the body's immune system and helps attack cancer cells.
Exosomes are extracellular vesicles with a size of 50 to 150 nanometers (nm), and exosomes secreted by cancer cells play a very decisive role in cancer proliferation and metastasis.
댓글